ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 2 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $329,526 | -48.3% | 29,501 | -0.9% | 0.00% | 0.0% |
Q2 2023 | $636,779 | -48.7% | 29,756 | -3.0% | 0.00% | -50.0% |
Q1 2023 | $1,240,901 | -16.6% | 30,685 | -4.1% | 0.00% | -33.3% |
Q4 2022 | $1,487,896 | -10.4% | 31,984 | -0.1% | 0.00% | 0.0% |
Q3 2022 | $1,660,000 | -18.3% | 32,002 | -25.6% | 0.00% | -25.0% |
Q2 2022 | $2,033,000 | +6.9% | 43,003 | +61.0% | 0.00% | +33.3% |
Q1 2022 | $1,901,000 | -11.5% | 26,710 | -7.1% | 0.00% | 0.0% |
Q4 2021 | $2,149,000 | +40.6% | 28,736 | -32.0% | 0.00% | 0.0% |
Q3 2015 | $1,528,000 | -17.5% | 42,278 | +2.6% | 0.00% | -25.0% |
Q2 2015 | $1,853,000 | +138.5% | 41,191 | +62.2% | 0.00% | +100.0% |
Q1 2015 | $777,000 | -41.9% | 25,393 | -3.4% | 0.00% | -33.3% |
Q4 2014 | $1,337,000 | +27.8% | 26,284 | -0.5% | 0.00% | +50.0% |
Q3 2014 | $1,046,000 | -6.4% | 26,427 | +1.8% | 0.00% | 0.0% |
Q2 2014 | $1,118,000 | +7.8% | 25,961 | +0.1% | 0.00% | 0.0% |
Q1 2014 | $1,037,000 | – | 25,929 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |